The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study
Gastroesophageal junction carcinoma (GEJC) and esophageal squamous cell carcinoma (ESCC) are increasing in Australia and other Western countries. We aimed to investigate past trends and predict the future direction of GEJC and ESCC cases. Data on GEJC and ESCC were extracted from the Australian Canc...
Gespeichert in:
Veröffentlicht in: | BMC cancer 2024-12, Vol.24 (1), p.1498 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 1498 |
container_title | BMC cancer |
container_volume | 24 |
creator | Mudiyanselage, Shalika Bohingamu Nguyen, Dieu Tang, Boxiong Williams, Rhys Kamal, Mostafa Zhao, Fei-Li Gao, Lan |
description | Gastroesophageal junction carcinoma (GEJC) and esophageal squamous cell carcinoma (ESCC) are increasing in Australia and other Western countries. We aimed to investigate past trends and predict the future direction of GEJC and ESCC cases.
Data on GEJC and ESCC were extracted from the Australian Cancer Database, and the National Mortality Database for the Australian states of Victoria, Queensland, Tasmania, and the Australian Capital Territory. The new number of cases were predicted up to 2039 by fitting a least squares linear regression using the Australian incidence rates trend from 2009 to 2018. Past trends were analyzed for prevalence and mortality. Kaplan-Meier curves generated the survival trend for up to 10 years.
Between 2009 and 2018, the overall incidences of GEJC showed an increasing trend (annual change [β
] = 0.87, P |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_39639209</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>39639209</sourcerecordid><originalsourceid>FETCH-pubmed_primary_396392093</originalsourceid><addsrcrecordid>eNqFz8FOAjEQBuCGxAAKr2DmBTbpssRlvRGj8QG4k6EdlpK2UzrbAy_js7oSjd48zX_4_j-ZiZrX67auVmvdztS9yFnrut3ozVTNmu6p6Va6m6uP3YmAkrMUHHvunUEPQ6ZoBTBaSJmsM4PjKMBHIOF0wp5GJJeCgYuAIe_BYDYucsBbq0cZMv_B5xJvI7_ueYSwLaND78aYOBWPX6Y6oJAFGYq9LtTdEb3Q8vs-qMe3193Le5XKIZDdp-wC5uv-56HmX_AJzJxbMw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Mudiyanselage, Shalika Bohingamu ; Nguyen, Dieu ; Tang, Boxiong ; Williams, Rhys ; Kamal, Mostafa ; Zhao, Fei-Li ; Gao, Lan</creator><creatorcontrib>Mudiyanselage, Shalika Bohingamu ; Nguyen, Dieu ; Tang, Boxiong ; Williams, Rhys ; Kamal, Mostafa ; Zhao, Fei-Li ; Gao, Lan</creatorcontrib><description>Gastroesophageal junction carcinoma (GEJC) and esophageal squamous cell carcinoma (ESCC) are increasing in Australia and other Western countries. We aimed to investigate past trends and predict the future direction of GEJC and ESCC cases.
Data on GEJC and ESCC were extracted from the Australian Cancer Database, and the National Mortality Database for the Australian states of Victoria, Queensland, Tasmania, and the Australian Capital Territory. The new number of cases were predicted up to 2039 by fitting a least squares linear regression using the Australian incidence rates trend from 2009 to 2018. Past trends were analyzed for prevalence and mortality. Kaplan-Meier curves generated the survival trend for up to 10 years.
Between 2009 and 2018, the overall incidences of GEJC showed an increasing trend (annual change [β
] = 0.87, P < 0.05). For GEJC, the rates of incidence, prevalence, and mortality were higher in men (β
= 1.86, 95% CI: 1.29-2.43, P < 0.05; β
= 14.45, 95% CI: 12.93-15.98, P < 0.05; β
= 1.04, 95% CI: - 0.68 to 2.76, P = 0.195, respectively) than in women. By 2039, it is estimated that 6 in 100,000 population will be newly diagnosed with GEJC. Notably, the rate of new GEJC cases decreased in women during the study period (β
=-0.08, 95% CI: - 0.39 to 0.24, P = 0.596). For ESCC, the incidence rate increased, albeit at a slower rate compared with GEJC (β
= 0.87, 95% CI: 0.6-1.15, P < 0.05; β
= 0.03, 95% CI: - 0.28 to 0.34, P = 0.805, respectively). New cases of ESCC in men declined (β
=-0.03, 95% CI: - 0.46 to 0.4, P = 0.884). By 2039, it is predicted that 2 in 100,000 people will be newly diagnosed. The 10-year survival rate for GEJC and ESCC was low (11% and 20%, respectively), while the survival rate for women was relatively higher than for men.
The incidence, prevalence, and mortality would be predicted to increase in 2039 if there were no significant changes in risk factors, diagnosis, treatment, and management compared with 2009-2018. Strategies to identify early signs and enable earlier diagnosis and early and new treatment options are essential in GEJC and ESCC.</description><identifier>EISSN: 1471-2407</identifier><identifier>PMID: 39639209</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Australia - epidemiology ; Esophageal Neoplasms - epidemiology ; Esophageal Neoplasms - mortality ; Esophageal Squamous Cell Carcinoma - epidemiology ; Esophageal Squamous Cell Carcinoma - mortality ; Esophageal Squamous Cell Carcinoma - pathology ; Esophagogastric Junction - pathology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prevalence ; Stomach Neoplasms - epidemiology ; Stomach Neoplasms - mortality</subject><ispartof>BMC cancer, 2024-12, Vol.24 (1), p.1498</ispartof><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39639209$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mudiyanselage, Shalika Bohingamu</creatorcontrib><creatorcontrib>Nguyen, Dieu</creatorcontrib><creatorcontrib>Tang, Boxiong</creatorcontrib><creatorcontrib>Williams, Rhys</creatorcontrib><creatorcontrib>Kamal, Mostafa</creatorcontrib><creatorcontrib>Zhao, Fei-Li</creatorcontrib><creatorcontrib>Gao, Lan</creatorcontrib><title>The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Gastroesophageal junction carcinoma (GEJC) and esophageal squamous cell carcinoma (ESCC) are increasing in Australia and other Western countries. We aimed to investigate past trends and predict the future direction of GEJC and ESCC cases.
Data on GEJC and ESCC were extracted from the Australian Cancer Database, and the National Mortality Database for the Australian states of Victoria, Queensland, Tasmania, and the Australian Capital Territory. The new number of cases were predicted up to 2039 by fitting a least squares linear regression using the Australian incidence rates trend from 2009 to 2018. Past trends were analyzed for prevalence and mortality. Kaplan-Meier curves generated the survival trend for up to 10 years.
Between 2009 and 2018, the overall incidences of GEJC showed an increasing trend (annual change [β
] = 0.87, P < 0.05). For GEJC, the rates of incidence, prevalence, and mortality were higher in men (β
= 1.86, 95% CI: 1.29-2.43, P < 0.05; β
= 14.45, 95% CI: 12.93-15.98, P < 0.05; β
= 1.04, 95% CI: - 0.68 to 2.76, P = 0.195, respectively) than in women. By 2039, it is estimated that 6 in 100,000 population will be newly diagnosed with GEJC. Notably, the rate of new GEJC cases decreased in women during the study period (β
=-0.08, 95% CI: - 0.39 to 0.24, P = 0.596). For ESCC, the incidence rate increased, albeit at a slower rate compared with GEJC (β
= 0.87, 95% CI: 0.6-1.15, P < 0.05; β
= 0.03, 95% CI: - 0.28 to 0.34, P = 0.805, respectively). New cases of ESCC in men declined (β
=-0.03, 95% CI: - 0.46 to 0.4, P = 0.884). By 2039, it is predicted that 2 in 100,000 people will be newly diagnosed. The 10-year survival rate for GEJC and ESCC was low (11% and 20%, respectively), while the survival rate for women was relatively higher than for men.
The incidence, prevalence, and mortality would be predicted to increase in 2039 if there were no significant changes in risk factors, diagnosis, treatment, and management compared with 2009-2018. Strategies to identify early signs and enable earlier diagnosis and early and new treatment options are essential in GEJC and ESCC.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Australia - epidemiology</subject><subject>Esophageal Neoplasms - epidemiology</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Squamous Cell Carcinoma - epidemiology</subject><subject>Esophageal Squamous Cell Carcinoma - mortality</subject><subject>Esophageal Squamous Cell Carcinoma - pathology</subject><subject>Esophagogastric Junction - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Stomach Neoplasms - epidemiology</subject><subject>Stomach Neoplasms - mortality</subject><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFz8FOAjEQBuCGxAAKr2DmBTbpssRlvRGj8QG4k6EdlpK2UzrbAy_js7oSjd48zX_4_j-ZiZrX67auVmvdztS9yFnrut3ozVTNmu6p6Va6m6uP3YmAkrMUHHvunUEPQ6ZoBTBaSJmsM4PjKMBHIOF0wp5GJJeCgYuAIe_BYDYucsBbq0cZMv_B5xJvI7_ueYSwLaND78aYOBWPX6Y6oJAFGYq9LtTdEb3Q8vs-qMe3193Le5XKIZDdp-wC5uv-56HmX_AJzJxbMw</recordid><startdate>20241205</startdate><enddate>20241205</enddate><creator>Mudiyanselage, Shalika Bohingamu</creator><creator>Nguyen, Dieu</creator><creator>Tang, Boxiong</creator><creator>Williams, Rhys</creator><creator>Kamal, Mostafa</creator><creator>Zhao, Fei-Li</creator><creator>Gao, Lan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20241205</creationdate><title>The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study</title><author>Mudiyanselage, Shalika Bohingamu ; Nguyen, Dieu ; Tang, Boxiong ; Williams, Rhys ; Kamal, Mostafa ; Zhao, Fei-Li ; Gao, Lan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_396392093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Australia - epidemiology</topic><topic>Esophageal Neoplasms - epidemiology</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Squamous Cell Carcinoma - epidemiology</topic><topic>Esophageal Squamous Cell Carcinoma - mortality</topic><topic>Esophageal Squamous Cell Carcinoma - pathology</topic><topic>Esophagogastric Junction - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Stomach Neoplasms - epidemiology</topic><topic>Stomach Neoplasms - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mudiyanselage, Shalika Bohingamu</creatorcontrib><creatorcontrib>Nguyen, Dieu</creatorcontrib><creatorcontrib>Tang, Boxiong</creatorcontrib><creatorcontrib>Williams, Rhys</creatorcontrib><creatorcontrib>Kamal, Mostafa</creatorcontrib><creatorcontrib>Zhao, Fei-Li</creatorcontrib><creatorcontrib>Gao, Lan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mudiyanselage, Shalika Bohingamu</au><au>Nguyen, Dieu</au><au>Tang, Boxiong</au><au>Williams, Rhys</au><au>Kamal, Mostafa</au><au>Zhao, Fei-Li</au><au>Gao, Lan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2024-12-05</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>1498</spage><pages>1498-</pages><eissn>1471-2407</eissn><abstract>Gastroesophageal junction carcinoma (GEJC) and esophageal squamous cell carcinoma (ESCC) are increasing in Australia and other Western countries. We aimed to investigate past trends and predict the future direction of GEJC and ESCC cases.
Data on GEJC and ESCC were extracted from the Australian Cancer Database, and the National Mortality Database for the Australian states of Victoria, Queensland, Tasmania, and the Australian Capital Territory. The new number of cases were predicted up to 2039 by fitting a least squares linear regression using the Australian incidence rates trend from 2009 to 2018. Past trends were analyzed for prevalence and mortality. Kaplan-Meier curves generated the survival trend for up to 10 years.
Between 2009 and 2018, the overall incidences of GEJC showed an increasing trend (annual change [β
] = 0.87, P < 0.05). For GEJC, the rates of incidence, prevalence, and mortality were higher in men (β
= 1.86, 95% CI: 1.29-2.43, P < 0.05; β
= 14.45, 95% CI: 12.93-15.98, P < 0.05; β
= 1.04, 95% CI: - 0.68 to 2.76, P = 0.195, respectively) than in women. By 2039, it is estimated that 6 in 100,000 population will be newly diagnosed with GEJC. Notably, the rate of new GEJC cases decreased in women during the study period (β
=-0.08, 95% CI: - 0.39 to 0.24, P = 0.596). For ESCC, the incidence rate increased, albeit at a slower rate compared with GEJC (β
= 0.87, 95% CI: 0.6-1.15, P < 0.05; β
= 0.03, 95% CI: - 0.28 to 0.34, P = 0.805, respectively). New cases of ESCC in men declined (β
=-0.03, 95% CI: - 0.46 to 0.4, P = 0.884). By 2039, it is predicted that 2 in 100,000 people will be newly diagnosed. The 10-year survival rate for GEJC and ESCC was low (11% and 20%, respectively), while the survival rate for women was relatively higher than for men.
The incidence, prevalence, and mortality would be predicted to increase in 2039 if there were no significant changes in risk factors, diagnosis, treatment, and management compared with 2009-2018. Strategies to identify early signs and enable earlier diagnosis and early and new treatment options are essential in GEJC and ESCC.</abstract><cop>England</cop><pmid>39639209</pmid></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1471-2407 |
ispartof | BMC cancer, 2024-12, Vol.24 (1), p.1498 |
issn | 1471-2407 |
language | eng |
recordid | cdi_pubmed_primary_39639209 |
source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adult Aged Aged, 80 and over Australia - epidemiology Esophageal Neoplasms - epidemiology Esophageal Neoplasms - mortality Esophageal Squamous Cell Carcinoma - epidemiology Esophageal Squamous Cell Carcinoma - mortality Esophageal Squamous Cell Carcinoma - pathology Esophagogastric Junction - pathology Female Humans Incidence Male Middle Aged Prevalence Stomach Neoplasms - epidemiology Stomach Neoplasms - mortality |
title | The epidemiological trends and predictions of esophageal squamous cell carcinoma and gastroesophageal junction carcinoma: an Australian population-based study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T00%3A31%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20epidemiological%20trends%20and%20predictions%20of%20esophageal%20squamous%20cell%20carcinoma%20and%20gastroesophageal%20junction%20carcinoma:%20an%20Australian%20population-based%20study&rft.jtitle=BMC%20cancer&rft.au=Mudiyanselage,%20Shalika%20Bohingamu&rft.date=2024-12-05&rft.volume=24&rft.issue=1&rft.spage=1498&rft.pages=1498-&rft.eissn=1471-2407&rft_id=info:doi/&rft_dat=%3Cpubmed%3E39639209%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/39639209&rfr_iscdi=true |